Aligos Therapeutics, Inc. (ALGS) Tops Q2 EPS by 20c

Aligos Therapeutics, Inc. (NASDAQ: ALGS) reported Q2 EPS of ($0.47), $0.20 better than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Aligos Therapeutics, Inc. (ALGS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79